Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 21 (2007), Suppl C, Pages 25C-34C
http://dx.doi.org/10.1155/2007/138245
Canadian Consensus Guidelines

Management of Chronic Hepatitis C: Consensus Guidelines

Morris Sherman,1 Stephen Shafran,2 Kelly Burak,3 Karen Doucette,2 Winnie Wong,2 Nigel Girgrah,1 Eric Yoshida,4 Eberhard Renner,5 Philip Wong,6 and Marc Deschênes6

1Department of Medicine, University of Toronto, Toronto, Ontario, Canada
2Department of Medicine, University of Alberta, Edmonton, Canada
3Department of Medicine, University of Calgary, Calgary, Alberta, Canada
4Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
5Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
6Department of Medicine, McGill University, Montreal, Quebec, Canada

Copyright © 2007 Canadian Association for the Study of the Liver. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.

Abstract

Since the last consensus conference on the management of chronic viral hepatitis, a number of studies looking at modifications of the standard course of treatment have been published. These changes have been sufficiently substantive to warrant review to determine whether any changes in the recommended treatment algorithms are needed. A consensus development conference was held in January 2007, and the present document highlights the results of the presentations and discussion about these issues. It reviews the epidemiology of hepatitis C in Canada, treatment of acute hepatitis C and new algorithms in chronic hepatitis C, including retreatment of previous treatment failures. In addition, sections on management of hepatitis C in special populations have been updated. There is also a section on the use of hematopoietic growth factors to help manage patients on therapy. The document should be read in conjunction with the previous document to identify changes. Some recommendations made in the previous document remain and are not discussed here.